WIRB-Copernicus Group Acquires Vigilare International

Food and Healthcare Press Releases Wednesday November 29, 2017 08:41
PRINCETON, New Jersey--29 Nov--PRNewswire/InfoQuest
  • WCG expands portfolio to include top pharmacovigilance, drug safety solution provider

WIRB Copernicus Group(R) (WCG(TM)), the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced its acquisition of Vigilare International, the top provider of integrated, end-to-end pharmacovigilance and drug safety solutions for the biopharmaceutical and biotech industry.

"We are delighted to welcome Vigilare to the WCG family of companies," said Donald A. Deieso, PhD, Chairman and CEO of WCG. "With its comprehensive service suite, Vigilare provides clients with streamlined, regulatory compliant operations, faster access to safety data and focused in-depth product safety reporting and analysis. Vigilare saves clients time and money by offering them a robust alternative to building and maintaining an internal pharmacovigilance and drug safety program."

"WCG is a perfect fit for Vigilare," said James A. Bannon, PharmD, President and CEO of Vigilare. "Our pharmacovigilance services are a natural complement to WCG's existing portfolio of clinical research optimization solutions. We look forward to working with our colleagues at WCG to identify additional opportunities to streamline clinical research operations, while improving the quality of product safety information."

Like the other members of the WCG family of companies, Vigilare will continue to operate as an independent service organization. WCG will support Vigilare as it continues to expand, with access to capital, complementary clinical and regulatory expertise, and corporate support.

Financial details about the transaction were not disclosed.
About WIRB-Copernicus Group

WIRB-Copernicus Group (WCG) is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. The industry's first clinical services organization (CSO), WCG enables biopharmaceutical companies, CROs, and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human subject protection. For more information, please visit www.wcgclinical.com or follow us on Twitter @WCGClinical.

About Vigilare International (Vigilare)

Vigilare offers product safety services in support of clinical trials and focused pharmacovigilance services in support of marketed products globally. Vigilare's experts are experienced healthcare practitioners working with every type of product, from drugs and devices to vaccines, to over-the-counter products and nutraceuticals.

Logo - https://mma.prnewswire.com/media/610823/WCG_Logo.jpg

Latest Press Release

Swift Biosciences Launches Accel-Amplicon Plus Cancer Panels for Precision Medicine Initiatives

- New targeted sequencing workflow combines pre-validated content with easy customization and new analysis tools to accelerate variant discovery and screening Swift Biosciences today announced the commercial release of its Accel-Amplicon Plus(TM) Cancer...

Sotera Health LLC announces intent to sell Nordion#s Medical Isotopes segment to BWXT

Sotera Health committed to Safeguarding Global Health(TM) with Nordion's increased focus on global gamma technologies business Sotera Health LLC, the world's leading, fully integrated protector of global health, today announced that it has entered into...

On World Hemophilia Day 2018, Shire Unites Communities in Asia Pacific and Advocates for #Principles of Care#

Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech leader in rare diseases, is marking World Hemophilia Day ( https://www.wfh.org/en/whd ) to drive greater awareness of hemophilia in Asia Pacific (APAC) and improve standards of care for people living...

Menarini Ricerche to Present the Most Recent Pre-clinical Data About the PI3K Inhibitor MEN1611 at the AACR Annual Meeting 2018

Menarini Ricerche will present on the latest preclinical studies of its phosphatidylinositol 3-kinase (PI3K) class I inhibitor MEN1611, in development for solid tumors, at the AACR Annual Meeting 2018, which will take place on April 14-18, 2018, in...

Medela: NICE Recommends Thopaz+ Portable, Digital System for Managing Chest Drains

- In multiple clinical trials patients with the Thopaz+ chest drainage system have had shorter chest tube placements and also shorter hospital stays than patients with conventional chest drains. - Chest surgery typically requires the insertion of a thin...

Related Topics